Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia

@article{Hanon2001NeuroprotectivePO,
  title={Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia},
  author={Etienne P Hanon and Henrik Klitgaard},
  journal={Seizure},
  year={2001},
  volume={10},
  pages={287-293},
  url={https://api.semanticscholar.org/CorpusID:18867231}
}
It is suggested that LEV possesses neuroprotective properties which may be relevant for its antiepileptogenic action and this was associated with hypothermia.

Figures and Tables from this paper

The Antiepileptic Drug Levetiracetam Suppresses Non-Convulsive Seizure Activity and Reduces Ischemic Brain Damage in Rats Subjected to Permanent Middle Cerebral Artery Occlusion

In rats subjected to pMCAO, a single Lev injection suppresses NCS occurrence for at least 24 hours, which could explain the long lasting reduction of ischemic brain damage caused by this drug.

The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum

The results of this study show a neuroprotective role and antioxidant action of LVT against the brain damage induced by excitotoxic events.

Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury.

Findings support the dual anti- seizure and neuroprotective role of LEV, but more importantly identify the importance of an extended dosing protocol which was specific to the therapeutic targets studied.

Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer’s disease

It is demonstrated that LEV alleviated hippocampal cell death and memory deficits in STZ-AD rats, through mitigating oxidative damage, suppression of proinflammatory cytokines expression, and inhibition of abnormal tau hyperphosphorylation.

Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats

The obtained results suggest that LCM pretreatment could be used as an effective neuroprotective method for neonates under hypoxic-ischemic conditions including heart surgery.

Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage

Levetiracetam is neuroprotective in clinically relevant animal models of SAH and closed head injury and may be a therapeutic alternative to phenytoin following acute brain injury in the clinical setting when seizure prophylaxis is indicated.
...

Cerebroprotective effect of lamotrigine after focal ischemia in rats.

The cerebroprotective effect of lamotrigine in rats is limited to a narrow dose range between 8 and 20 mg/kg, and may be useful when given shortly after the onset of stroke.

Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.

The powerful antiepileptogenic activity of levetiracetam in the kindling model indicates that levetIRacetam is not only an interesting novel drug for symptomatic treatment of epilepsy but might be suited for pharmacological prevention of this disease in patients with a high prospective risk of the development of epilepsy.

The neuroprotective action of dizocilpine (MK‐801) in the rat middle cerebral artery occlusion model of focal ischaemia

The minimum effective plasma concentration of dizocilpine (MK‐801) was 8.0 ng ml−1, although the greatest protection was seen with a plasma level of 18.9 ng ml‐1, which correlates well with the concentration of MK‐801 required to block N‐methyl‐d‐aspartate (NMDA) receptors and prevent NMDA receptor mediated neurotoxicity in vitro.

Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man.

The balance between these potential adverse effects and the anti-ischaemic efficacy of these drugs will ultimately determine the clinical utility of this class of drugs.

Postischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus

It is suggested that tiagabine slows the development of hippocampal degeneration following ischemia, and that mild, postischemic hypothermia is responsible, in large part, for the neuroprotective actions of this drug.